Trial Profile
A Pilot Study Combining ABT-888, an Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Failed Up to Two Non-hormonal Systemic Therapies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Temozolomide
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors AbbVie
- 04 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Sep 2012 Actual end date added as reported by ClinicalTrials.gov.
- 15 Jun 2011 Planned end date changed from Jun 2011 to Jul 2011 as reported by ClinicalTrials.gov.